Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer

Inclusion Criteria:

• Female participants, with at least 18 years old on the day of signing the free andinformed consent;

• Invasive breast carcinoma stage III (RH positive) or IIB/III (RH negative),according to TNM 8th edition; Histologically confirmed diagnosis of invasive breastcarcinoma (with any histology), HER-2 negative;

• The participant (or legally acceptable representative, if applicable) provideswritten informed consent for the study;

• The participant must agree to use a contraceptive as detailed in Appendix B of thisprotocol during the treatment period and for at least 120 days after the last doseof the study treatment;

• Have a functional capacity according to the Eastern Cooperative Oncology Group (ECOG) from 0 to 2. The evaluation of the ECOG must be carried out within 7 daysbefore the inclusion date.

• Have adequate organic function. The samples must be collected within 60 days beforethe start of the study treatment;

• Have adequate cardiac function as assessed by echocardiogram or MUGA performed up to 60 days before the start of treatment under study.

Exclusion Criteria:

• Individuals who do not meet the inclusion criteria above-mentioned.